Orthocell (ASX: OCC), a regenerative medicine company focused on tissue repair, has announced a significant breakthrough with the successful completion of a first surgery in the United States using its Remplir technology. Orthocell is dedicated to developing innovative solutions for regenerative medicine, including cell therapies and collagen scaffold devices. Remplir is their trademarked nerve repair product.
The surgery, performed by doctors at a hospital in Ohio, involved repairing a foot injury using Remplir. This achievement follows Orthocell’s recent clearance for Remplir’s use in the US, a market estimated to be worth $2.4 billion. According to chief executive officer Paul Anderson, this first US surgery represents a major milestone for Orthocell and the Remplir rollout in the US, marking the commencement of its commercial activities in the world’s largest healthcare and nerve repair markets.
Orthocell appointed 14 specialist distributors in April 2025 to facilitate adoption across key regions. The inaugural surgery was a direct result of a distributor’s established relationship with a nerve repair surgeon in Ohio. Mr. Anderson stated that a critical first step is ensuring surgeons are familiar with Remplir’s key features and benefits in clinical practice, adding that these early cases play an important strategic role in building knowledge within the surgical community.
Manufactured in Perth, Australia, Remplir is a collagen wrap employed in nerve repair surgery designed to enhance the regeneration of damaged nerves and improve patient outcomes. Orthocell estimates the global nerve repair market to be valued at over $5.3 billion, with approximately 2 million peripheral nerve repairs performed annually. With around A$30 million in cash reserves and no debt, the company is well-positioned to expand its commercial footprint and increase revenues in both existing and new markets. The company anticipates material growth in Remplir sales during the second half of calendar 2025.
